Genmab — April 2020
-
Mine tre største positioner i pharma er Genmab, Novo og J&J. De er næsten alle i ATH. Tålmodighed belønnes.
-
summary : Daratumumab was approved in Taiwan for the treatment of adult patients with relapsed and refractory multiple myeloma in 2017, and was included in the health insurance benefits in April 2020. https://udn.com/news/story/7266/4511829
-
AlphaValue har add target 1672 senest opdateret på Bloomberg den 16.04.2020
-
overvægt eller køb vil jeg mene
-
ja godt forslag
-
Hold da op, jeg er desværre ude af GMAB lige for tiden. Men i dag er der indledt dækning fra Credit Suisse
-
We initiate coverage of Genmab with an Outperform rating (TP DKK1,950). Genmab is a Danish Biopharma founded on a novel antibody platform. Success has been built on partnerships with Novartis (on Arzerra) and JNJ (on Darzalex), providing Genmab with cash and validation to expand its antibody discovery strategy. The investment thesis has moved beyond Darzalex, for which we think forecasts are well reflected (CSe USD 10bn peak; c17% royalty). Focus now switches to the pipeline as it prepares to be
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind